SA112340005B1 - صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coa - Google Patents
صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coaInfo
- Publication number
- SA112340005B1 SA112340005B1 SA112340005A SA112340005A SA112340005B1 SA 112340005 B1 SA112340005 B1 SA 112340005B1 SA 112340005 A SA112340005 A SA 112340005A SA 112340005 A SA112340005 A SA 112340005A SA 112340005 B1 SA112340005 B1 SA 112340005B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- formulation
- omega
- fatty acid
- present
- hmg
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
يتعلق الاختراع الحالي بصيغة معقدة عن طريق الفم oral مشتملة على : omega-3 fatty acid أو مشتقاته مكبسلة في كبسولة صلبة أو طرية محتوية على sorbitol وsorbitan ، وأيضاً مثبط إنزيم reductase HMG-CoA. توفر صيغة الاختراع الحالي المشتمل على omega-3 fatty acid مكبسل مع sorbitol وsorbitan منع أفضل من أن يتم تكوين مواد متعلقة، مما يؤدي إلى ثبات تخزين طويل المدى محسن. يمكن أن ترفع الصيغة المعقدة عن طريق الفم oral للاختراع الحالي أيضاً مستوى المصل cholesterol - HDL، مع خفض كلا مستويي cholesterol - LDL وTG. تكون الصيغة المعقدة عن طريق الفم oral للاختراع الحالي مفيدة لعلاج فرط دهن الدم. شكل 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110120493 | 2011-11-17 | ||
KR1020120128926A KR101466617B1 (ko) | 2011-11-17 | 2012-11-14 | 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
SA112340005B1 true SA112340005B1 (ar) | 2015-07-09 |
Family
ID=48663604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA112340005A SA112340005B1 (ar) | 2011-11-17 | 2012-11-17 | صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coa |
Country Status (11)
Country | Link |
---|---|
US (1) | US20140314844A1 (ar) |
EP (1) | EP2780002A4 (ar) |
JP (1) | JP6073352B2 (ar) |
KR (1) | KR101466617B1 (ar) |
CN (1) | CN103957896A (ar) |
AR (1) | AR088876A1 (ar) |
HK (1) | HK1199396A1 (ar) |
SA (1) | SA112340005B1 (ar) |
TW (1) | TW201328727A (ar) |
UY (1) | UY34455A (ar) |
WO (1) | WO2013073884A1 (ar) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016024844A1 (ko) * | 2014-08-13 | 2016-02-18 | 한국유나이티드제약 주식회사 | 오메가-3 지방산 에스테르 및 스타틴계 약물을 포함하는 경구용 복합제제 |
TWI525110B (zh) * | 2014-12-24 | 2016-03-11 | 財團法人工業技術研究院 | 聚合物、及包含其之醫藥組合物 |
WO2017171484A1 (ko) * | 2016-03-31 | 2017-10-05 | 한미약품 주식회사 | 오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제 |
KR102108154B1 (ko) * | 2017-02-08 | 2020-05-07 | (주)동구바이오제약 | 개선된 생체이용률을 갖는 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 복합제제 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
GB8305693D0 (en) * | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
DE3307353C2 (de) * | 1983-03-02 | 1985-01-31 | R.P. Scherer GmbH, 6930 Eberbach | Polyethylenglykolhaltige Weichgelatinekapsel und Verfahren zu ihrer Herstellung |
US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
US4963385A (en) * | 1989-06-02 | 1990-10-16 | Nabisco Brands, Inc. | Stabilized emulsions containing highly unsaturated oils |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
WO1994016693A1 (en) * | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
GB9313329D0 (en) * | 1993-06-28 | 1993-08-11 | Scherer Ltd R P | Softgel capsule shell compositions |
GB9706149D0 (en) * | 1997-03-25 | 1997-05-14 | Scherer Corp R P | Comestible capsules having flavoured coatings |
CZ20023826A3 (cs) * | 2000-06-09 | 2003-04-16 | Lek Pharmaceuticals D. D. | Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující |
US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
ES2255426B1 (es) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
WO2006062748A2 (en) * | 2004-12-06 | 2006-06-15 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
JP5628480B2 (ja) * | 2006-03-09 | 2014-11-19 | グラクソスミスクライン エルエルシー | 医薬成分を含有するコーティングカプセル |
AU2007258941B2 (en) * | 2006-06-16 | 2013-08-01 | Cipla Limited | Improved dry powder inhaler |
ITFI20060162A1 (it) * | 2006-06-26 | 2007-12-27 | Valpharma Sa | Composizione farmaceutica per la somministrazione orale di acidi grassi omega polienoici ed uno o piu' principi attivi con essi incompatibili, e processo per la sua preparazione. |
WO2008000731A2 (en) | 2006-06-26 | 2008-01-03 | Valpharma S.A. | Pharmaceutical composition for the oral administration of omega polyenoic fatty acids |
US20100285121A1 (en) * | 2008-01-10 | 2010-11-11 | Takeda Pharmaceutical Company Limited | Capsule Formulation |
WO2009127974A2 (ko) * | 2008-02-22 | 2009-10-22 | 한올제약주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
US8933255B2 (en) * | 2008-12-31 | 2015-01-13 | Nitromega Corp. | Nutraceuticals containing nitro fatty acids |
JP5313343B2 (ja) * | 2009-05-22 | 2013-10-09 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
-
2012
- 2012-11-14 KR KR1020120128926A patent/KR101466617B1/ko active IP Right Grant
- 2012-11-15 AR ARP120104299A patent/AR088876A1/es unknown
- 2012-11-16 CN CN201280056897.9A patent/CN103957896A/zh active Pending
- 2012-11-16 JP JP2014542243A patent/JP6073352B2/ja not_active Expired - Fee Related
- 2012-11-16 EP EP12850234.1A patent/EP2780002A4/en not_active Withdrawn
- 2012-11-16 WO PCT/KR2012/009718 patent/WO2013073884A1/en active Application Filing
- 2012-11-16 US US14/358,853 patent/US20140314844A1/en not_active Abandoned
- 2012-11-16 UY UY0001034455A patent/UY34455A/es not_active Application Discontinuation
- 2012-11-16 TW TW101142820A patent/TW201328727A/zh unknown
- 2012-11-17 SA SA112340005A patent/SA112340005B1/ar unknown
-
2014
- 2014-12-24 HK HK14112885.7A patent/HK1199396A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AR088876A1 (es) | 2014-07-16 |
UY34455A (es) | 2013-06-28 |
HK1199396A1 (en) | 2015-07-03 |
WO2013073884A1 (en) | 2013-05-23 |
CN103957896A (zh) | 2014-07-30 |
KR20130054921A (ko) | 2013-05-27 |
US20140314844A1 (en) | 2014-10-23 |
KR101466617B1 (ko) | 2014-11-28 |
EP2780002A4 (en) | 2015-05-27 |
JP2014533685A (ja) | 2014-12-15 |
JP6073352B2 (ja) | 2017-02-01 |
EP2780002A1 (en) | 2014-09-24 |
TW201328727A (zh) | 2013-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA106457C2 (ru) | Пероральная комплексная композиция, содержащая сложные эфиры жирной кислоты омега-3 и ингибитор hmg-coa редуктазы | |
PH12016500216B1 (en) | Stable pharmaceutical composition and methods of using same | |
JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
WO2011153157A3 (en) | Benzoquinolone inhibitors of vmat2 | |
MX2019010602A (es) | Inhibidores de cdk. | |
MD20140136A2 (ro) | Inhibitori ai virusului hepatic C | |
TN2012000543A1 (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
MX2011012523A (es) | Esteres cetalicos de anhidropentitoles y usos de los mismos. | |
MY184914A (en) | Methods of administering pirfenidone theraphy | |
IN2014DN09370A (ar) | ||
SI2576580T1 (sl) | Znižanje nivoja laktata in zvišanje produkcije polipeptida z znižanjem ravni izražanja laktat-dehidrogenaze in piruvat-dehidrogenaza-kinaze | |
SG194469A1 (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
IN2013MN00501A (ar) | ||
WO2012049307A3 (en) | Novel n-terminally modified insulin derivatives | |
MX2013007436A (es) | Uso de estabilizadores de glutamina. | |
MX340033B (es) | Derivados heterobiciclicos como inhibidores del virus de la hepatitis c. | |
MX2015008135A (es) | Composiciones para evitar olores que incluye microorganismos inodoros. | |
SA112340005B1 (ar) | صيغة من حمض دهني أوميجا-3ومثبط إنزيم ريدكتيزhmg -coa | |
MY167897A (en) | A compound separated from monascus-fermented rice, the preparation method and uses thereof | |
MD20160001A2 (ro) | Utilizarea unei formulări orale pentru tratamentul bolilor cardiovasculare | |
WO2011093828A3 (en) | Solid dosage forms comprising cefprozil | |
WO2011002161A3 (en) | Transdermal composition comprising tolterodine | |
EP2727591A3 (en) | Stable pharmaceutical compositions containing cefaclor and clavulanic acid | |
WO2012083408A8 (pt) | Composições farmacêuticas antimaláricas contendo derivados de diterpenos caurânicos | |
WO2010129505A3 (en) | Napthylene inhibitors of cyclooxygenase |